| MRI | Magnetic Resonance Imaging; Àڱ⠰ø¸í ¿µ»ó |
|---|---|
| B1 | induced field in magnetic resonance imaging; radiofrequency magnetic field in nuclear magnetic reson... |
| BEI | back-scattered electron imaging; biological exposure indexes; butanol-extractable iodine |
| CDE | canine distemper encephalitis; chlordiazepoxide; color Doppler energy [imaging]; common duct explora... |
| CDI | cell-directed inhibitor; central or chronic diabetes insipidus; Children's Depression Inventory; col... |
| thyroid imaging | <radiology> Tc-99m pertechnetate 6 mCi, I-123 sodium iodide 200 - 400 uCi PO (12 Dec 1998) |
|---|---|
| transfer imaging | The production of an ultrasound image by detection and analysis of sound on the opposite side of the body from the emitting transducer. Synonym: through transfer imaging. (05 Mar 2000) |
| ultrasound imaging | <investigation, procedure> A technique in which high-frequency sound waves are bounced off internal organs and the echo pattern is converted into a 2 dimensional picture of the structures beneath the transducer. (12 May 1997) |
| kidney: gallium imaging | <radiology> 10-20% of Ga-67 excreted via GU tract; no renal activity after 24hrs abnormal uptake (images at 48-72 hrs): tumour, primary renal tumour (variable uptake), lymphoma/leukaemia, metastases (e.g., melanoma), inflammation, acute pyelonephritis (88% sensitivity); abscess, lobar nephroma, others, collagen vascular disease, vasculitis, Wegener granulomatosis, amyloidosis, haemochromatosis, hepatic failure, antineoplastic drugs, transplant rejection: acute, chronic, ATN see also: gallium: indications (12 Dec 1998) |
| liver metastases: ultrasound imaging | <radiology> Echogenic (25%), colonic carcinoma, hepatocellular carcinoma, treated breast carcinoma mixed echogenicity (37.5%), breast carcinoma, rectal carcinoma, lung carcinoma, stomach carcinoma, anaplastic cancer, cervical carcinoma, carcinoid hypoechoic (37.5%), lymphoma, pancreatic carcinoma, cervical carcinoma, lung carcinoma (adenocarcinoma), nasopharyngeal carcinoma see: liver metastases (12 Dec 1998) |
| lung: gallium imaging | <radiology> Scans at 48 hrs because 50% of normals show activity at 24 hrs, focal uptake, primary pulmonary malignancy, benign disorder: granuloma, abscess, pneumonia, silicosis, multifocal/diffuse uptake, infection, TB: active lesion, miliary TB, rapidly progressive TB pneumonia, PCP: unimpressive symptoms and CXR, CMV, inflammation: sarcoid, interstitial lung disease (pneumoconiosis, idiopathic pulmonary fibrosis, lymphangitic carcinomatosis), radiation pneumonitis, drugs: bleomycin, amiodarone, contrast lymphangiography (in 50%) see: gallium: indications, uptake with normal chest film (12 Dec 1998) |
| abortifacient agents | Chemical substances that interrupt pregnancy after implantation. (12 Dec 1998) |
| abortifacient agents, non-steroidal | Non-steroidal chemical compounds with abortifacient activity. (12 Dec 1998) |
| abortifacient agents, steroidal | Steroidal compounds with abortifacient activity. (12 Dec 1998) |
| adrenergic agents | Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters. (12 Dec 1998) |
| alkylating agents | Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agent, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases. (12 Dec 1998) |
| anti-allergic agents | Agents that are used to treat allergic reactions. most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (12 Dec 1998) |
| anti-allergic and respiratory system agents | A collective term for drugs used to treat allergic reactions as well as those drugs that produce an effect on the respiratory system. (12 Dec 1998) |
| anti-anxiety agents | Agents that alleviate anxiety, tension, and neurotic symptoms, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. Some are also effective as anticonvulsants, muscle relaxants, or anaesthesia adjuvants. Adrenergic beta-antagonists are commonly used in the symptomatic treatment of anxiety but are not included here. Substances with a benzodiazepine ring structure widely used to treat anxiety and neuroses. Drugs in this class also generally have sedative or weak hypnotic properties and may be effective as muscle relaxants, anticonvulsants, and anaesthesia adjuvants. (12 Dec 1998) |
| anti-arrhythmia agents | Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|